OncoMatch/Clinical Trials/NCT07106827
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Is NCT07106827 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GV20-0251 for hcc - hepatocellular carcinoma.
Treatment: GV20-0251 — This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Cholangiocarcinoma
Melanoma
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Head and Neck Squamous Cell Carcinoma
Endometrial Cancer
Testicular Germ Cell Tumor
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care therapy
Refractory or intolerant to standard therapies, must have received the standard of care therapy
Cannot have received: anticancer therapy
Exception: allowed if >4 weeks or >5 half-lives before first dose of GV20-0251
Prior anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GV20-0251 on Cycle 1 Day 1 (C1D1), with the exceptions.
Cannot have received: radiation therapy
Exception: allowed if >14 days before C1D1 dosing
Radiation therapy for symptomatic lesions within 14 days prior to C1D1 dosing.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify